CELL INTELLIGENCE · 肿瘤细胞治疗研究

线粒体适应度作为癌症中的功能性免疫检查点：代谢可塑性、肿瘤演化与免疫治疗

Mitochondrial Fitness as a Functional Immune Checkpoint in Cancer: Metabolic Plasticity, Tumor Evolution, and Immunotherapy.

PI3K-beta Inhibitor GSK2636771 治疗淋巴瘤、肿瘤：II 期临床试验

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Scr

这是一项 II 期、非随机的注册临床试验，评估细胞治疗用于淋巴瘤、肿瘤、膀胱癌的疗效与安全性。研究设计：非随机、8 个分组。登记适应症还包括乳腺癌、宫颈癌、结直肠癌、子宫内膜癌、食管癌、胃癌等（登记共 52 项）。当前状态：进行中（不再招募）。计划入组 6452 例。试验地点：美国 · 伯明翰、费尔霍普、莫比尔、安克雷奇（共 1410 个中心）。登记号：NCT02465060。

辐照 CD19 嵌合抗原受体 YTS 细胞保留抗肿瘤活性并可作为自体 CAR-T 疗法的可规模化替代方案

Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy.

实体瘤 CAR-T 细胞工程化：克服抗原、迁移与微环境屏障

Engineering CAR-T cells for solid tumors: overcoming antigenic, trafficking, and microenvironmental barriers.

可编程工程菌调控代谢并原位重塑 TME 以增强过继性细胞治疗

Programmable engineered bacteria manipulate metabolism and remodel the TME in situ for enhancing adoptive cell therapy.

超越传统嵌合抗原受体：拓展 CAR-T 细胞疗法中的可靶向抗原版图

Beyond Conventional Chimeric Antigen Receptors: Expanding the Targetable Antigen Landscape in Chimeric Antigen Receptor-T Cell Therapy.

CAR-T 细胞治疗指南：研发、现状与未来前景

A guide to CAR T cell therapies: development, current status and future prospects.

2024 EBMT 活动报告：跨越 100 万例造血细胞移植和 20, 000 例 CAR-T，细胞治疗领域的里程碑

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

CAR 疗法在肿瘤与自身免疫领域的演进：机制见解与治疗创新

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.

CAR-T 细胞基因治疗的综合评价：追溯其革命性临床突破与迈向下一代工程的进展

A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engin

基于这些进展，我们假设 CAR-T 疗法正经历从单靶点细胞毒性向多功能、可编程框架的范式转变，该框架能够克服耐药性、增强安全性，并实现实体瘤的有效渗透。